Hoe verhoudt MBOT's PB Ratio zich tot zijn concurrenten?

MBOT is duur op basis van de Price-To-Book -ratio ( 4.4 x) vergeleken met het gemiddelde van de peer ( 1 x).

Hoe verhoudt MBOT's PB Ratio zich tot andere bedrijven in de US Medical Equipment industrie?

MBOT is duur op basis van de Price-To-Book -ratio ( 4.4 x) vergeleken met het US Medical Equipment -industriegemiddelde ( 2.6 x).

Wat is MBOT's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { MBOT te berekenen voor waarderinganalyse.

Wat is de reële prijs van MBOT als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van MBOT te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Microbot Medical (Nasdaq:MBOT) - Aandelenkoers, Nieuws & Analyse

MBOT Overzicht aandelen

MBOT fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 8.3% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Microbot Medical Inc. Concurrenten

Ekso Bionics Holdings

NasdaqCM:EKSO

US$15.2m

Autonomix Medical

NasdaqCM:AMIX

US$7.3m

Lifeward

NasdaqCM:LFWD

US$18.2m

Cue Health

NasdaqCM:HLTH

US$14.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Microbot Medical
Historische aandelenkoersen
Huidige aandelenkoers	US$0.99
52 Week Hoogtepunt	US$2.35
52 Week Laag	US$0.82
Bèta	1.63
11 maand verandering	1.35%
3 maanden verandering	4.52%
1 Jaar Verandering	-24.43%
33 jaar verandering	-80.70%
5 jaar verandering	-79.67%
Verandering sinds IPO	-99.35%

Recent nieuws en updates

Recent updates

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Dec 30

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Sep 01

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Dec 28

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

Dec 24

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Aug 27

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

May 12

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Jan 27

Microbot Medical's study of surgical robotic system meets endpoints

Jan 14

Rendement voor aandeelhouders

	MBOT	US Medical Equipment	US Markt
7D	7.1%	1.2%	2.0%
1Y	-24.4%	22.6%	32.4%

Rendement versus industrie: MBOT presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.6 % opleverde.

Rendement versus markt: MBOT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is MBOT's price volatile compared to industry and market?
MBOT volatility
MBOT Average Weekly Movement	6.7%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: MBOT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MBOT is het afgelopen jaar gedaald van 13% naar 7%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	22	Harel Gadot	microbotmedical.com

Microbot Medical Inc., een preklinisch bedrijf voor medische apparatuur, houdt zich bezig met onderzoek, ontwerp en ontwikkeling van endoluminale chirurgische robotapparaten gericht op minimaal invasieve chirurgie. Het bedrijf biedt LIBERTY, een endovasculair robotchirurgisch systeem waarmee artsen een kathetergebaseerde procedure kunnen uitvoeren buiten het katheterisatielaboratorium, en stralingsblootstelling, fysieke belasting en het risico op kruisbesmetting kunnen vermijden voor gebruik in cardiovasculaire, perifere en neurovasculaire ruimten. Het bedrijf levert ook NovaCross, een intellectueel eigendom en technologie op het gebied van intraluminale revascularisatiehulpmiddelen met verankeringsmechanisme en geïntegreerde microkatheter.

Microbot Medical Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Microbot Medical zich tot de beurswaarde?
MBOT fundamentele statistieken
Marktkapitalisatie	US$16.76m
Inkomsten(TTM)	-US$11.20m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.5x

Koers/Winstverhouding

Is MBOT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MBOT resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$11.21m
Inkomsten	-US$11.20m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.66
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MBOT op de lange termijn?

Bekijk historische prestaties en vergelijking

MBOT Overzicht aandelen

Risicoanalyse

Microbot Medical Inc. Concurrenten

NasdaqCM:EKSO

US$15.2m

NasdaqCM:AMIX

US$7.3m

NasdaqCM:LFWD

US$18.2m

NasdaqCM:HLTH

US$14.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Recent updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New minor risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Price target decreased by 60% to US$8.00

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Price target decreased by 58% to US$8.00

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical acquires Nitiloop, terms undisclosed

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical confirms GLP trial on track to begin later this month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022